Medically reviewed by Alan Lucks | MD , Alan Lucks MDPC Private Practice - New York on February 26th, 2026
Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands
Regular health monitoring Baseline testing before starting: Complete blood count (CBC) Comprehensive metabolic panel (liver, kidney function) Fasting glucose and insulin IGF-1 levels Thyroid panel (TSH, T3, T4) Follow-up testing: Every 3-6 months while using peptides Immediately if concerning symptoms Compare to baseline What to monitor: Blood sugar regulation Liver and kidney function Thyroid function IGF-1 levels (shouldn't be excessively elevated) Lipid profile When to stop: Any concerning blood markers Persistent side effects Signs of organ stress Unusual symptoms Cycling and breaks For growth hormone peptides: CJC-1295 + Ipamorelin: Can use 3-6+ months continuously GHRP-6: Cycle 8-12 weeks, break 4-8 weeks Hexarelin: Cycle 4 weeks, break 4+ weeks (not recommended for most) For healing peptides: BPC-157: Can use continuously TB-500: Can use continuously or cycle 8-16 weeks on, 4-8 weeks off GHK-Cu: Can use continuously Why breaks matter: Prevent receptor desensitization Allow natural hormone production to recover Reduce long-term risk Reset tolerance See peptide cycle planning guide and can you cycle different peptides
1), can lead to PM-mediated adverse health effects
A 10mg vial reconstituted with 2mL bacteriostatic water yields a 5mg/mL concentration, allowing precise dosing in 100mcg increments using standard insulin syringe markings
Oh et al
